Annals of clinical and translational neurology · 2026
Clinical Impact of NOTCH3 Variant Location After First Stroke in CADASIL.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aguilhon Léa, Chabriat Hugues, Hervé Dominique, Guey Stéphanie, Du Montcel Sophie Tezenas, Ortholand Juliette
Аннотация
OBJECTIVE: Despite its monogenic origin, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy exhibits marked variability in clinical expression and severity. Variants in the NOTCH3 gene, within epidermal growth factor-like repeat domains 1-6 or 7-34, are known to influence disease onset, but their impact on long-term progression remains unclear. This study assesses mutation location effects on post-first stroke clinical trajectories.
METHODS: Clinical data from a large cohort were analyzed (Patients EGFR 1-6 mutation group n = 210 and 7-34 mutation group n = 116) with target emulated trial framework. To study the impact of mutation location on stroke recurrence, disability (modified Rankin score ≥ 3) and mortality, following a first stroke event. Propensity score matching was used to balance covariates between mutation location groups and principal stratification to consider truncation by death. Events occurrence differences were compared using Restricted Mean Survival Time at 2, 5, 10 and 15 years.
RESULTS: At first stroke, patients with mutation in domains 1-6 were younger than those in the 7-34 mutation group (49.51 ± 7.4 vs. 55.00 ± 7.4 years). Ten years after first stroke event, mortality occurred slightly later in the 7-34 group (9.63 [9.33-9.92] vs. 9.11 [8.71-9.52] years, p = 0.04), also at 15 years (14.0 [13.42-14.63] vs. 12.4 [11.62-13.24] years; p = 0.002). Second stroke occurrence did not differ between groups. Time beyond modified Rankin of 3 slightly differed between groups at 5 and 10 years, with a difference of 0.22 [0.01-0.044] and 0.72 [0.14-1.30] year respectively (p = 0.044 and 0.017).
INTERPRETATION: Although NOTCH3 variants location influences the delay to the first stroke, it has no or little impact on the recurrence of stroke, risk of disability and death after the first stroke manifestation.
METHODS: Clinical data from a large cohort were analyzed (Patients EGFR 1-6 mutation group n = 210 and 7-34 mutation group n = 116) with target emulated trial framework. To study the impact of mutation location on stroke recurrence, disability (modified Rankin score ≥ 3) and mortality, following a first stroke event. Propensity score matching was used to balance covariates between mutation location groups and principal stratification to consider truncation by death. Events occurrence differences were compared using Restricted Mean Survival Time at 2, 5, 10 and 15 years.
RESULTS: At first stroke, patients with mutation in domains 1-6 were younger than those in the 7-34 mutation group (49.51 ± 7.4 vs. 55.00 ± 7.4 years). Ten years after first stroke event, mortality occurred slightly later in the 7-34 group (9.63 [9.33-9.92] vs. 9.11 [8.71-9.52] years, p = 0.04), also at 15 years (14.0 [13.42-14.63] vs. 12.4 [11.62-13.24] years; p = 0.002). Second stroke occurrence did not differ between groups. Time beyond modified Rankin of 3 slightly differed between groups at 5 and 10 years, with a difference of 0.22 [0.01-0.044] and 0.72 [0.14-1.30] year respectively (p = 0.044 and 0.017).
INTERPRETATION: Although NOTCH3 variants location influences the delay to the first stroke, it has no or little impact on the recurrence of stroke, risk of disability and death after the first stroke manifestation.